These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 5289421)

  • 1. Some biochemical and pharmacologic properties of amethopterin-albumin.
    Jacobs SA; D'Urso-Scott M; Bertino JR
    Ann N Y Acad Sci; 1971 Nov; 186():284-6. PubMed ID: 5289421
    [No Abstract]   [Full Text] [Related]  

  • 2. Discussion paper: amethopterin linked covalently to water-soluble macromolecules.
    Harding NG
    Ann N Y Acad Sci; 1971 Nov; 186():270-83. PubMed ID: 5002437
    [No Abstract]   [Full Text] [Related]  

  • 3. The interaction of carrier-bound methotrexate with L1210 cells.
    Chu BC; Whiteley JM
    Mol Pharmacol; 1980 May; 17(3):382-7. PubMed ID: 6156401
    [No Abstract]   [Full Text] [Related]  

  • 4. Growth inhibitory, transport and biochemical properties of the gamma-glutamyl and gamma-aspartyl peptides of methotrexate in L1210 leukemia cells in vitro.
    Sirotnak FM; Chello PL; Piper JR; Montgomery JA
    Biochem Pharmacol; 1978; 27(14):1821-5. PubMed ID: 708463
    [No Abstract]   [Full Text] [Related]  

  • 5. Deaza aalogues of amethopterin (methotrexate).
    Montgomery JA; Elliott RD; Straight SL; Temple C
    Ann N Y Acad Sci; 1971 Nov; 186():227-34. PubMed ID: 5002299
    [No Abstract]   [Full Text] [Related]  

  • 6. Reduced forms of aminopterin and methotrexate in L1210 lymphoma.
    Makulu DR; Fölsch E
    J Natl Cancer Inst; 1977 Jul; 59(1):245-9. PubMed ID: 875056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fluorescent derivative of methotrexate as an intracellular marker for dihydrofolate reductase in L1210 cells.
    Henderson GB; Russell A; Whiteley JM
    Arch Biochem Biophys; 1980 Jun; 202(1):29-34. PubMed ID: 6772112
    [No Abstract]   [Full Text] [Related]  

  • 8. Sites of action of amethopterin: intrinsic and acquired drug resistance.
    Harrap KR; Hill BT; Furness ME; Hart LI
    Ann N Y Acad Sci; 1971 Nov; 186():312-24. PubMed ID: 5289423
    [No Abstract]   [Full Text] [Related]  

  • 9. On the nature of a transport alteration determining resistance to amethopterin in the L1210 leukemia.
    Sirotnak FM; Kurita S; Hutchison DJ
    Cancer Res; 1968 Jan; 28(1):75-80. PubMed ID: 5635374
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of 4-amino-4-deoxy-N10-methylpteroic acid and methotrexate transport by mouse leukemia cells.
    Kessel D
    Mol Pharmacol; 1969 Jan; 5(1):21-5. PubMed ID: 5392912
    [No Abstract]   [Full Text] [Related]  

  • 11. Antineoplastic activity of lipid-soluble dialkyl esters of methotrexate.
    Johns DG; Farquhar D; Chabner BA; Wolpert MK; Adamson RH
    Experientia; 1973 Sep; 29(9):1104-5. PubMed ID: 4744861
    [No Abstract]   [Full Text] [Related]  

  • 12. A model system for the study of heteroexchange diffusion: methotrexate-folate interactions in L1210 leukemia and Ehrlich ascites tumor cells.
    Goldman ID
    Biochim Biophys Acta; 1971 Jun; 233(3):624-34. PubMed ID: 5113921
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversibility of high-affinity binding of methotrexate in L1210 murine leukemia cells.
    Cohen M; Bender RA; Donehower R; Myers CE; Chabner BA
    Cancer Res; 1978 Sep; 38(9):2866-70. PubMed ID: 679194
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia.
    Mead JA; Goldin A; Kisliuk RL; Friedkin M; Plante L; Crawford EJ; Kwok G
    Cancer Res; 1966 Nov; 26(11):2374-9. PubMed ID: 4959533
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia.
    Sirotnak FM; Donsbach RC
    Cancer Res; 1973 Jun; 33(6):1290-4. PubMed ID: 4718678
    [No Abstract]   [Full Text] [Related]  

  • 16. Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice.
    Sirotnak FM; DeGraw JI; Chello PL; Moccio DM; Dorick DM
    Cancer Treat Rep; 1982 Feb; 66(2):351-8. PubMed ID: 7055818
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in the biochemical pharmacology of folic acid antagonists.
    Loo TL; Johns DG; Farquhar D
    Transplant Proc; 1973 Sep; 5(3):1161-5. PubMed ID: 4728815
    [No Abstract]   [Full Text] [Related]  

  • 18. Folic acid antagonists. Methotrexate analogs containing spurious amino acids. Dichlorohomofolic acid.
    Lee WW; Martinez AP; Goodman L
    J Med Chem; 1974 Mar; 17(3):326-30. PubMed ID: 4811228
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose methotrexate therapy with citrovorum factor: a pharmacologic perspective in murine tumor models.
    Sirotnak FM; Donsbach RC; Dorick DM; Moccio DM
    Cancer Treat Rep; 1977 Jul; 61(4):565-74. PubMed ID: 301778
    [No Abstract]   [Full Text] [Related]  

  • 20. The basis for the disparate sensitivity of L1210 leukemia and Walker 256 carcinoma to a new triazine folate antagonist.
    Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
    Cancer Res; 1973 Nov; 33(11):2972-6. PubMed ID: 4748449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.